vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $257.2M, roughly 1.3× WESBANCO INC). WESBANCO INC runs the higher net margin — 34.5% vs 13.2%, a 21.3% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
HAE vs WSBC — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $257.2M |
| Net Profit | $44.7M | $88.6M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | — |
| Net Margin | 13.2% | 34.5% |
| Revenue YoY | -2.7% | — |
| Net Profit YoY | 19.3% | 54.4% |
| EPS (diluted) | $0.95 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $339.0M | $265.6M | ||
| Q3 25 | $327.3M | $261.6M | ||
| Q2 25 | $321.4M | $260.7M | ||
| Q1 25 | $330.6M | $193.2M | ||
| Q4 24 | $348.5M | $162.9M | ||
| Q3 24 | $345.5M | $150.8M | ||
| Q2 24 | $336.2M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $44.7M | $91.1M | ||
| Q3 25 | $38.7M | $83.6M | ||
| Q2 25 | $34.0M | $57.4M | ||
| Q1 25 | $58.0M | $-9.0M | ||
| Q4 24 | $37.5M | $49.6M | ||
| Q3 24 | $33.8M | $37.3M | ||
| Q2 24 | $38.4M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | 43.2% | ||
| Q3 25 | 17.9% | 39.5% | ||
| Q2 25 | 16.8% | 27.2% | ||
| Q1 25 | 21.6% | -5.0% | ||
| Q4 24 | 16.9% | 38.0% | ||
| Q3 24 | 15.0% | 29.7% | ||
| Q2 24 | 11.8% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | 13.2% | 34.3% | ||
| Q3 25 | 11.8% | 31.9% | ||
| Q2 25 | 10.6% | 22.0% | ||
| Q1 25 | 17.5% | -4.7% | ||
| Q4 24 | 10.8% | 30.5% | ||
| Q3 24 | 9.8% | 24.7% | ||
| Q2 24 | 11.4% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.95 | $0.97 | ||
| Q3 25 | $0.81 | $0.84 | ||
| Q2 25 | $0.70 | $0.57 | ||
| Q1 25 | $1.17 | $-0.15 | ||
| Q4 24 | $0.74 | $0.72 | ||
| Q3 24 | $0.66 | $0.54 | ||
| Q2 24 | $0.74 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | — |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $4.1B |
| Total Assets | $2.5B | $27.5B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $363.4M | $956.1M | ||
| Q3 25 | $296.4M | $1.0B | ||
| Q2 25 | $292.9M | $1.2B | ||
| Q1 25 | $306.8M | $1.1B | ||
| Q4 24 | $320.8M | $568.1M | ||
| Q3 24 | $299.3M | $620.9M | ||
| Q2 24 | $344.4M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $911.5M | $4.0B | ||
| Q3 25 | $849.2M | $4.1B | ||
| Q2 25 | $882.3M | $3.8B | ||
| Q1 25 | $820.8M | $3.8B | ||
| Q4 24 | $906.9M | $2.8B | ||
| Q3 24 | $878.9M | $2.8B | ||
| Q2 24 | $905.4M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $2.5B | $27.7B | ||
| Q3 25 | $2.4B | $27.5B | ||
| Q2 25 | $2.5B | $27.6B | ||
| Q1 25 | $2.5B | $27.4B | ||
| Q4 24 | $2.5B | $18.7B | ||
| Q3 24 | $2.5B | $18.5B | ||
| Q2 24 | $2.5B | $18.1B |
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | — |
| Free Cash FlowOCF − Capex | $87.2M | — |
| FCF MarginFCF / Revenue | 25.7% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $93.6M | $290.4M | ||
| Q3 25 | $111.3M | $116.9M | ||
| Q2 25 | $17.4M | $105.0M | ||
| Q1 25 | $116.6M | $-26.4M | ||
| Q4 24 | $43.8M | $211.0M | ||
| Q3 24 | $48.8M | $60.7M | ||
| Q2 24 | $-27.4M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $87.2M | $280.0M | ||
| Q3 25 | $106.3M | $114.9M | ||
| Q2 25 | $13.6M | $98.3M | ||
| Q1 25 | $100.9M | $-30.7M | ||
| Q4 24 | $35.2M | $200.7M | ||
| Q3 24 | $39.4M | $56.9M | ||
| Q2 24 | $-33.1M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | 105.4% | ||
| Q3 25 | 32.5% | 43.9% | ||
| Q2 25 | 4.2% | 37.7% | ||
| Q1 25 | 30.5% | -15.9% | ||
| Q4 24 | 10.1% | 123.2% | ||
| Q3 24 | 11.4% | 37.7% | ||
| Q2 24 | -9.8% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 3.9% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 4.7% | 2.2% | ||
| Q4 24 | 2.5% | 6.3% | ||
| Q3 24 | 2.7% | 2.5% | ||
| Q2 24 | 1.7% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | 3.19× | ||
| Q3 25 | 2.88× | 1.40× | ||
| Q2 25 | 0.51× | 1.83× | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | 4.25× | ||
| Q3 24 | 1.44× | 1.63× | ||
| Q2 24 | -0.71× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
